Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.

Kukendrarajah K, Farmaki AE, Lambiase PD, Schilling R, Finan C, Floriaan Schmidt A, Providencia R

Open source

DOI
10.1016/j.ebiom.2024.105194
Published
2024 Jul
Container
EBioMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2024.105194,
  title = {Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.},
  author = {Kukendrarajah K and Farmaki AE and Lambiase PD and Schilling R and Finan C and Floriaan Schmidt A and Providencia R},
  year = {2024},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2024.105194},
  url = {https://doi.org/10.1016/j.ebiom.2024.105194}
}

RIS

TY  - JOUR
TI  - Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.
AU  - Kukendrarajah K
AU  - Farmaki AE
AU  - Lambiase PD
AU  - Schilling R
AU  - Finan C
AU  - Floriaan Schmidt A
AU  - Providencia R
PY  - 2024
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2024.105194
UR  - https://doi.org/10.1016/j.ebiom.2024.105194
ER  - 

APA

K, K., AE, F., PD, L., R, S., C, F., A, F. S., & R, P. (2024). Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2024.105194

Source records